Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer

Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer

Abstract Background CDK4/6 inhibitors (CDK4/6i) have shown promising results in the treatment of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) when combined with endocrine therapy (ET). It is crucial to evaluate the actual effectiveness and safety of CDK4/6i in clinical practice, as...

Full description

Saved in:
Bibliographic Details
Main Authors: Binliang Liu, Zhe‐Yu Hu, Ning Xie, Liping Liu, Jing Li, Xiaohong Yang, Huawu Xiao, Xuran Zhao, Can Tian, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Quchang Ouyang
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Cancer Innovation
Subjects:
breast cancer
CDK4/6 inhibitor
efficacy
predictive factors
real‐word study
Online Access:https://doi.org/10.1002/cai2.143
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cai2.143

Similar Items